NeoGenomics, Inc.
NASDAQ:NEOMedical - Diagnostics & Research
+$0.63 today
- Market cap
- $1.99B
- Beta
- 1.81
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.84
Volume 1.09M
Average 1.94M
NEO EBITDA Margin
EBITDA as a percentage of revenue.
NeoGenomics, Inc.NASDAQ: NEO
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to 9.3%
EBITDA Margin was 9.3% in Q2 FY2026, up 24.6 pp from a year earlier. On a trailing-twelve-month basis it was 1.7%, up 5.8 pp year over year. Over 3 fiscal years it widened by 10.8 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 8 analysts of 12.5% for the fiscal year ending Dec 2026, up from -5.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 9.3%+9.6 pp QoQ
- Last fiscal yearDec 2025
- -5.3%-5.1 pp YoY
- LTMJun 2026
- 1.7%+5.8 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +24.6 pp | +17.7 pp | -6.8 pp |
| 1 year | -5.1 pp | +17.9 pp | +22.9 pp |
| 3 years | +10.8 pp | +19.2 pp | +8.4 pp |
| 5 years | +22.7 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -5.3%
- Year-over-year change
- -5.1pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -5.3% | -5.1pp |
| FY2024 | 2024-12-31 | -0.2% | +2.7pp |
| FY2023 | 2023-12-31 | -3.0% | +13.2pp |
| FY2022 | 2022-12-31 | -16.2% | -25.8pp |
| FY2021 | 2021-12-31 | 9.6% | — |
EBITDA Margin vs competitors
How NEO compares with its peers on the latest reported figures
- NEO's LTM Jun 2026 EBITDA Margin of 1.7% is the 2nd highest of the 10 companies compared; the peer median is -19.1%.
- Its year-over-year change of +5.8 pp is the 4th highest of 10, against a peer median of +1.5 pp.
- Over three fiscal years its change of +10.8 pp compares with a peer median of +87.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 23.1% | +13.6 pp | +20.8 pp | |
| LTM Jun 2026 | 1.7% | +5.8 pp | +10.8 pp | |
| LTM Mar 2026 | -0.2% | -12.0 pp | +45.9 pp | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | -16.8% | -24.5 pp | +171.2 pp |
| LTM Mar 2026 | -18.9% | +1.5 pp | +75.6 pp | |
| LTM Mar 2026 | -19.1% | +17.8 pp | +110.1 pp | |
| LTM Sep 2026 | -34.5% | +4.7 pp | +98.7 pp | |
| LTM Mar 2026 | -40.3% | -32.6 pp | -27.6 pp | |
| LTM Mar 2026 | -132.6% | -47.0 pp | — | |
| LTM Jun 2026 | -226.4% | +86.1 pp | +801.0 pp | |
FRNMFreenome, Inc. Common stock | — | — | — | — |
| Peer median (excluding NEO) | -19.1% | +1.5 pp | +87.2 pp | |
Competitors are the stored peer set for NEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 484.33M | 509.73M | 591.64M | 660.57M | 727.33M |
| Cost of Revenue | 297.27M | 321.83M | 347.04M | 370.47M | 444.79M |
| Gross Profit | 187.06M | 187.9M | 244.6M | 290.1M | 282.54M |
| Gross Margin | 38.6% | 36.9% | 41.3% | 43.9% | 38.8% |
| Research & Development | 21.87M | 30.33M | 27.31M | 31.16M | 37.08M |
| Selling, General & Admin | 283.94M | 277.91M | 279.96M | 310.49M | 365.34M |
| Operating Expenses | 305.81M | 345.52M | 352.34M | 382.21M | 348.62M |
| Depreciation & Amortization | 53.35M | 69.43M | 72.58M | 72.55M | 67.82M |
| EBITDA | 46.5M | (82.33M) | (17.61M) | (1.51M) | (38.69M) |
| EBITDA Margin | 9.6% | -16.2% | -3.0% | -0.2% | -5.3% |
| Operating Income | (118.75M) | (157.62M) | (107.74M) | (92.11M) | (66.08M) |
| Operating Margin | -24.5% | -30.9% | -18.2% | -13.9% | -9.1% |
| Interest Income | 3.14M | 6.08M | 16.9M | 18.43M | 9.07M |
| Interest Expense | 8.22M | 7.58M | 6.91M | 6.62M | 3.75M |
| Other Income / Expenses | 103.68M | (1.72M) | 10.64M | 11.43M | (44.19M) |
| Income Before Tax | (15.08M) | (159.34M) | (97.1M) | (80.68M) | (110.27M) |
| Pre-Tax Margin | -3.1% | -31.3% | -16.4% | -12.2% | -15.2% |
| Income Tax Expense | (6.73M) | (15.09M) | (9.13M) | (1.95M) | (2.24M) |
| Net Income | (8.35M) | (144.25M) | (87.97M) | (78.73M) | (108.03M) |
| Net Margin | -1.7% | -28.3% | -14.9% | -11.9% | -14.9% |
| EPS (Basic) | (0.07) | (1.16) | (0.70) | (0.62) | (0.84) |
| EPS (Diluted) | (0.07) | (1.16) | (0.70) | (0.62) | (0.84) |
| Weighted Avg Shares | 119.96M | 124.22M | 125.5M | 126.66M | 128.1M |
| Weighted Avg Shares (Diluted) | 119.96M | 124.22M | 125.5M | 126.66M | 128.1M |
NeoGenomics, Inc.
NASDAQ:NEO
Intrinsic Alpha fair value
Locked
Current Price
$15.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.